Results 141 to 150 of about 22,928,755 (240)

Prognostic implications of functional significance, high-risk plaque and vessel characteristics in patients with diabetes mellitus. [PDF]

open access: yesKorean J Intern Med
Song JE   +15 more
europepmc   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm   +2 more
wiley   +1 more source

Dnmt3a Mutations Limit Normal and Autoreactive CD4+ T Follicular Helper Responses and Attenuate T Cell–Driven Joint Inflammation

open access: yesArthritis &Rheumatology, EarlyView.
Objective Somatic DNMT3A mutations are the most common drivers of clonal hematopoiesis in patients with rheumatoid arthritis (RA) and have been associated with seropositive disease and increased markers of inflammation. These mutations are predominantly hypomorphic or dominant‐negative, reducing DNMT3A function.
Yunbing Shen   +10 more
wiley   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease   +20 more
wiley   +1 more source

Sustained Inhibition of Structural Damage Progression and Improvements in Disease Activity With Guselkumab in Biologic‐Naïve Participants with Active and Erosive Psoriatic Arthritis: Results Through Week 48 of the Phase 3b Randomized, Double‐Blind, Placebo‐Controlled APEX Study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective In APEX, guselkumab, which binds to the IL‐23p19 subunit and CD64 on IL‐23‐producing cells, demonstrated significant joint efficacy and inhibition of structural damage progression in participants with active and erosive PsA through Week (W)24; W48 findings are reported herein. Methods The APEX modified full analysis set included 1020 biologic‐
Christopher T. Ritchlin   +12 more
wiley   +1 more source

Association of Lp(a) with coronary plaque burden and high-risk plaque features: A meta-analysis of imaging studies. [PDF]

open access: yesAtherosclerosis
Sebastian SA   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy